Goldman Sachs analyst Rajan Sharma reiterated a Buy rating on Argenx and raised his price target on the shares to EUR453. The analyst, who has the stock on the firm’s Conviction List, said that he is positive on Argenx given its strong execution on Vyvgart, which has consistently beaten consensus revenue expectations since its launch in 1Q22.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ARGX:
- argenx Appoints Ana Cespedes to Board of Directors
- argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
- Halozyme price target raised to $68 from $55 at Benchmark
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- William Blair starts Argenx with Outperform on ‘best-in-class’ product
